CORRESPONDENCE: OUR EXPERIENCE
SerenoCem™ granules in mastoid obliteration surgery: A 2-year follow-up case series of 55 patients to determine the risk of progressive bone resorption
Matthew Cherko,
Corresponding Author
Matthew Cherko
Department of Otorhinolaryngology, Wexham Park Hospital, Slough, UK
Correspondence
Matthew Cherko, Department of Otorhinolayngology, John Radcliffe Hospital, Headley Way, Headington, Oxford, OX3 9DU,
Email: [email protected]
Search for more papers by this author Laura Harrison,
Laura Harrison
Department of Otorhinolaryngology, Wexham Park Hospital, Slough, UK
Search for more papers by this author Gaurav Chawdhary,
Gaurav Chawdhary
Department of Otorhinolaryngology, Wexham Park Hospital, Slough, UK
Search for more papers by this author Matthew Bull,
Matthew Bull
Department of Radiology, Wexham Park Hospital, Slough, UK
Search for more papers by this author Ian Bottrill,
Ian Bottrill
Department of Otorhinolaryngology, John Radcliffe Hospital, Oxford, UK
Search for more papers by this author Christopher Aldren,
Christopher Aldren
Department of Otorhinolaryngology, Wexham Park Hospital, Slough, UK
Search for more papers by this author
Matthew Cherko,
Corresponding Author
Matthew Cherko
Department of Otorhinolaryngology, Wexham Park Hospital, Slough, UK
Correspondence
Matthew Cherko, Department of Otorhinolayngology, John Radcliffe Hospital, Headley Way, Headington, Oxford, OX3 9DU,
Email: [email protected]
Search for more papers by this author Laura Harrison,
Laura Harrison
Department of Otorhinolaryngology, Wexham Park Hospital, Slough, UK
Search for more papers by this author Gaurav Chawdhary,
Gaurav Chawdhary
Department of Otorhinolaryngology, Wexham Park Hospital, Slough, UK
Search for more papers by this author Matthew Bull,
Matthew Bull
Department of Radiology, Wexham Park Hospital, Slough, UK
Search for more papers by this author Ian Bottrill,
Ian Bottrill
Department of Otorhinolaryngology, John Radcliffe Hospital, Oxford, UK
Search for more papers by this author Christopher Aldren,
Christopher Aldren
Department of Otorhinolaryngology, Wexham Park Hospital, Slough, UK
Search for more papers by this author
First published: 25 August 2019
No abstract is available for this article.
CONFLICTS OF INTEREST
None to declare.
REFERENCES
- 1Harrison L, Kumar S, Bull M, Hatton PV, Bottrill I, Aldren C. Clinical case series describes a contraindication for SerenoCem GranulesTM in mastoid obliteration: Our experience in sixty-four patients. Clin Otol. 2017; 42: 1095-1100.
- 2 Medicines and Healthcare products Regulatory Agency. Medical device alert: SerenoCem Granules – risk of bone reabsorption around granules; 2016. MDA/2016/013. https://mhra.filecamp.com/public/file/2rrh-fo62n0qq. Accessed August 1, 2018.
